Conversely, treatment with antagomiR-503 in TAC mice improved cardiac function and decreased both transforming growth factor (TGF)-β and connective tissue growth factor (CTGF) expression, indicating that miR-503 has the potential to promote cardiac fibrosis [37]. This evidence concerns the gene TGFB1 and persistent truncus arteriosus.